Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 1:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pulmonary Disease Clear all
Completed No phase listed Observational Results available

Characteristics and Treatment Patterns of Patients With Chronic Obstructive Pulmonary Disease (COPD), Initiating Tio+Olo or Other Maintenance Therapies in the US and the UK: A Retrospective Claims Database Study

NCT04926233
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium bromide + Olodaterol, Sp(t)iolto® Respimat®
Drug · Device
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
1,371,146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 14, 2021 · Synced Sep 29, 2026, 1:59 AM EDT
Completed Not applicable Interventional Results available

Improving Goals of Care Discussion in Advanced Cancer Patients

NCT02374255
View directory record Official record
Conditions
Primary Stage IV Hepatobiliary, Esophageal, Colorectal Cancer, Glioblastoma, Cancer of Stomach, Cancer of Pancreas, Melanoma, Head or Neck Cancer, Stage III, Stage IV, Lung Cancers, Pancreatic Cancers
Interventions
GoC intervention
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
21 Years and older
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
4
States / cities
New Haven, Connecticut • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Sep 29, 2026, 1:59 AM EDT
Completed Not applicable Interventional

Improving Resection Rates Among African Americans With NSCLC

NCT01885455
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
Usual Care, Intervention Arm
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
21 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
10
States / cities
Lewes, Delaware • Savannah, Georgia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Sep 29, 2026, 1:59 AM EDT
Completed Not applicable Interventional

EPVent 2- A Phase II Study of Mechanical Ventilation Directed by Transpulmonary Pressures

NCT01681225
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome
Interventions
Esophageal-pressure guided mechanical ventilation, High PEEP mechanical ventilation
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
16 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
10
States / cities
La Jolla, California • Stanford, California • Orlando, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Sep 29, 2026, 1:59 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase I/II Trial of RAD001 Plus Docetaxel in Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer

NCT00406276
View directory record Official record
Conditions
Lung Cancer
Interventions
RAD001, Docetaxel
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 22, 2013 · Synced Sep 29, 2026, 1:59 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

NCT06472076
View directory record Official record
Conditions
Lung Cancer, Non-Small Cell
Interventions
Dostarlimab, Belrestotug, Pembrolizumab, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
Ocala, Florida • Honolulu, Hawaii • Lexington, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 29, 2026, 1:59 AM EDT
Completed No phase listed Observational

Viral Infection and Respiratory Illness Universal Study[VIRUS]: COVID-19 Registry

NCT04323787
View directory record Official record
Conditions
Coronavirus
Interventions
observational
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
Not listed
Enrollment
100,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
4
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Sep 29, 2026, 1:59 AM EDT
Recruiting No phase listed Observational

A Prospective, Multicenter, Single-arm MAC-PD Cohort: a NTM-NET and ESGMYC Collaborative Study

NCT05906316
View directory record Official record
Conditions
Mycobacterium Avium Complex Pulmonary Disease
Interventions
Not listed
Lead sponsor
Radboud University Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 29, 2026, 1:59 AM EDT
Terminated No phase listed Observational

Synchronized Intermittent Mechanical Ventilation Versus Open Lung Ventilation With Spontaneous Respiration

NCT00891085
View directory record Official record
Conditions
Trauma
Interventions
Not listed
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated May 18, 2023 · Synced Sep 29, 2026, 1:59 AM EDT
Recruiting Phase 2Phase 3 Interventional

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

NCT06236438
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Livmoniplimab, Budigalimab, Pembrolizumab, Pemetrexed, Cisplatin, Carboplatin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
19
States / cities
La Jolla, California • Pembroke Pines, Florida • Winter Haven, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 29, 2026, 1:59 AM EDT
Terminated Phase 2 Interventional Results available

Phase II Docetaxel / Carboplatin / XRT + Surgical Resection in Stage III NSCLC

NCT00238615
View directory record Official record
Conditions
Lung Cancer, Carcinoma, Non-Small-Cell Lung
Interventions
Docetaxel, Carboplatin, Radiation therapy, Surgical resection
Drug · Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 11, 2015 · Synced Sep 29, 2026, 1:59 AM EDT
Not listed Phase 2 Interventional

Docetaxel and Vinorelbine Plus Filgrastim in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00006215
View directory record Official record
Conditions
Lung Cancer
Interventions
filgrastim, docetaxel, vinorelbine tartrate
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
19
States / cities
Modesto, California • Washington D.C., District of Columbia • Riverdale, Georgia + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Sep 29, 2026, 1:59 AM EDT
Completed Phase 2 Interventional Results available

A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1

NCT02855125
View directory record Official record
Conditions
Advanced or Metastatic Non-small Cell Lung Cancer
Interventions
TAS-114, S-1
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
6
States / cities
Loma Linda, California • Gainesville, Florida • Cleveland, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 29, 2026, 1:59 AM EDT
Recruiting Not applicable Interventional

Pulmonary Artery Catheter in Cardiogenic Shock Trial

NCT05485376
View directory record Official record
Conditions
Cardiogenic Shock, Heart Failure
Interventions
Pulmonary Artery Catheter
Device
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Sep 29, 2026, 1:59 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Aerosolized Hypertonic Xylitol Versus Hypertonic Saline in Cystic Fibrosis (CF) Subjects

NCT00928135
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Xylitol, Hypertonic saline
Drug
Lead sponsor
Joseph Zabner
Other
Eligibility
12 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Sep 29, 2026, 1:59 AM EDT
Completed No phase listed Observational

U.S. CTEPH Registry

NCT02429284
View directory record Official record
Conditions
Chronic Thromboembolic Pulmonary Hypertension (CTEPH), Pulmonary Hypertension
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
Not listed
Enrollment
754 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2020 · Synced Sep 29, 2026, 1:59 AM EDT
Completed Not applicable Interventional

Sample Collection for Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel.

NCT05354115
View directory record Official record
Conditions
COVID-19, Influenza A, Influenza Type B
Interventions
Nasal and Nasopharyngeal Sampling of the Panbio™ COVID-19/ Flu A&B Rapid Panel
Diagnostic Test
Lead sponsor
Abbott Rapid Dx
Industry
Eligibility
14 Years to 100 Years
Enrollment
676 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Easley, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 8, 2023 · Synced Sep 29, 2026, 1:59 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of ULTRASE® MT20 in Participants With Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (PI)

NCT00408317
View directory record Official record
Conditions
Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Interventions
Ultrase® MT20, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
7 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
4
States / cities
Grand Rapids, Michigan • Cleveland, Ohio • Hershey, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Sep 29, 2026, 1:59 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Improving Cardiovascular Health in Patients With Chronic Obstructive Pulmonary Disease

NCT03819517
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Resveratrol, Placebo
Drug · Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 28, 2024 · Synced Sep 29, 2026, 1:59 AM EDT
Terminated Phase 2 Interventional

Oxaliplatin/CPT-11 for Extensive Stage Small Cell Lung Cancer

NCT00316433
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Irinotecan (CPT-11), Oxaliplatin (Eloxatin)
Drug
Lead sponsor
Swedish Medical Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 4, 2007 · Synced Sep 29, 2026, 1:59 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cardiovascular Vulnerability to Particulate Exposure

NCT00013949
View directory record Official record
Conditions
Heart Disease, Lung Disease
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
50 Years to 90 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 3, 2006 · Synced Sep 29, 2026, 1:59 AM EDT
Terminated Phase 1 Interventional

Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway

NCT06287463
View directory record Official record
Conditions
Advanced Solid Tumor, RAF Mutation, RAS Mutation, NF1 Mutation, Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Melanoma, BRAF Gene Mutation, CRAF Gene Mutation, Castration-Resistant Prostate Cancer (CRPC)
Interventions
DCC-3084
Drug
Lead sponsor
Deciphera Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
9
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Sep 29, 2026, 1:59 AM EDT
Completed Phase 2 Interventional Results available

Citrulline in Severe Sepsis

NCT01474863
View directory record Official record
Conditions
Severe Sepsis, Acute Lung Injury
Interventions
High Dose Citrulline, Placebo, Low Dose Citrulline
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
13 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 4, 2017 · Synced Sep 29, 2026, 1:59 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy With or Without Surgery & Chemoradiotherapy in Patients With Malignant Pleural Mesothelioma

NCT00354393
View directory record Official record
Conditions
Malignant Mesothelioma
Interventions
Cisplatin, Methotrexate, Vinorelbine ditartrate, Adjuvant therapy, Conventional surgery, Neoadjuvant Therapy, 3-dimensional conformal radiation therapy, Intensity-modulated radiation therapy
Drug · Procedure · Radiation
Lead sponsor
The Cleveland Clinic
Other
Eligibility
Up to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Sep 29, 2026, 1:59 AM EDT